![Nyxoah, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (Image courtesy of Nyxoah)](http://koreabizwire.com/wp/wp-content/uploads/2023/11/CMCK2LCLVVAYPACQWW322OZ2JQ-1.jpg)
Nyxoah, a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (Image courtesy of Nyxoah)
REGULATED INFORMATION
Information on the total number of voting rights and shares
Mont-Saint-Guibert, Belgium, Jun. 3 (Korea Bizwire) – In accordance with article 15 of the Law of 2 May 2007 on the disclosure of large shareholdings, Nyxoah SA (Euronext Brussels and Nasdaq: NYXH) publishes the below information following the issue of new shares.
- Share capital: EUR 5,902,793.43
- Total number of securities carrying voting rights: 34,360,390 (all ordinary shares)
- Total number of voting rights (= denominator): 34,360,390 (all relating to ordinary shares)
- Number of rights to subscribe to securities carrying voting rights not yet issued:
-
- 100 “2018 ESOP Warrants” issued on December 12, 2018, entitling their holders to subscribe to a total number of 50,000 securities carrying voting rights (all ordinary shares);
- 400,500 “2020 ESOP Warrants” issued on February 21, 2020, entitling their holders to subscribe to a total number of 400,500 securities carrying voting rights (all ordinary shares); and
- 1,070,500 “2021 ESOP Warrants” issued on September 8, 2021, entitling their holders to subscribe to a total number of 1,070,500 securities carrying voting rights (all ordinary shares); and
- 700,000 “2022 ESOP Warrants” issued on December 28, 2022, entitling their holders to subscribe to a total number of 700,000 securities carrying voting rights (all ordinary shares).
*
* *
Contact:
Nyxoah
David DeMartino, Chief Strategy Officer
IR@nyxoah.com
Attachment
Source: Nyxoah via GLOBE NEWSWIRE